|Bid||2.620 x 1800|
|Ask||2.620 x 900|
|Day's Range||2.5700 - 2.7200|
|52 Week Range||2.0800 - 5.9400|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2019 - Mar 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.25|
Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.
Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 10:00 a.m. PT (1:00 p.m. ET) at the Westin Saint Francis Hotel in San Francisco, CA. Dr. Berrey will present a corporate overview with plans and expected milestones for 2019, which will highlight the Company's core focus on progressing both oral, short-course brincidofovir (BCV) and the intravenous (IV) BCV program. Following planned discussions with FDA, the Company intends to progress IV BCV into a proof-of-concept study for the treatment of BK virus in kidney transplant recipients, while completing the phase 2 studies initiated during 2018 of IV BCV in adult stem cell transplant recipients with adenovirus infection.
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in October, blaming macroeconomic conditions and unpredictable events that hit several sectors, with healthcare among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent declines. […]
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
M. Berrey became the CEO of Chimerix, Inc. (NASDAQ:CMRX) in 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we Read More...
The Durham, North Carolina-based company said it had a loss of 33 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- Conference Call at 8:30 a.m. ET Today - DURHAM, N.C., Nov. 08, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address.
DURHAM, N.C., Nov. 07, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today.
The number of public companies based in the Triangle has shrunk in recent years as acquisitions have meant a change in headquarters location, or even taking the company private.
DURHAM, N.C., Nov. 01, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced.
Chimerix (CMRX) today announced data from two preclinical studies which assessed the in vivo antiviral activity of brincidofovir (BCV) against polyomavirus. Polyomaviruses are a family of small DNA viruses that persistently infect their hosts for life.
If you’re interested in Chimerix Inc (NASDAQ:CMRX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
Chimerix (CMRX) delivered earnings and revenue surprises of 11.36% and 27.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?